直肠癌全程新辅助治疗后完全缓解的临床与治疗预测因素:多中心分析
这项回顾性多中心分析纳入2015至2024年间接受全程新辅助治疗(TNT)的245例直肠癌患者,113例(46.1%)达到完全缓解(CR)。每增加一个巩固化疗周期CR概率提高(OR 1.19),短程放疗(SCRT)与较低CR率相关(OR 0.34),非吸烟者CR更可能(OR 1.92),同步奥沙利铂未进一步增加CR率。
要点
- 巩固化疗周期数增加与CR率提高独立相关(每周期OR 1.19)。
- SCRT较同步嘧啶类放化疗的CR率更低(OR 0.34)。
- 非吸烟者CR概率更高(OR 1.92),但需外部验证。
核心结论
- 更密集的TNT方案与更高的CR率相关,SCRT与较低CR率相关,非吸烟与更高CR率相关,同步奥沙利铂未进一步增加CR率。
研究设计与样本
- 回顾性多中心分析(DRKS00033000),纳入2015至2024年接受根治性TNT的直肠癌患者245例(男181例),中位年龄62岁(Q1-Q3:54-67)。
- 主要终点为CR,预设临床与治疗变量作为协变量,在多变量logistic回归模型中评估CR的潜在预测因素。
主要发现
- 245例中113例(46.1%)达到CR,其中69例(28.2%)为 active smokers。
- 107例(43.7%)接受SCRT;65例(26.5%)接受嘧啶类单药同步放化疗,73例(29.8%)接受联合同步奥沙利铂的放化疗。
- 巩固化疗中位8个周期(Q1-Q3:6-9);每增加一个化疗周期CR似然增加(OR 1.19,95%CI 1.04-1.38)。
- SCRT相比同步嘧啶类放化疗与更低CR率相关(OR 0.34,95%CI 0.16-0.74)。
- 5-FU基础上联合同步奥沙利铂未进一步增加CR率(OR 1.06,95%CI 0.50-2.27);非吸烟者CR更可能(OR 1.92,95%CI 1.03-3.57)。
关键数值与推荐
- ESMO肿瘤分类与治疗时长未与CR相关。
临床怎么用
- 在制定TNT方案时,可考虑增加巩固化疗周期数以提高CR率,为NOM创造条件。
- 选择放疗模式时需权衡SCRT与同步放化疗对CR率的影响。
- 对吸烟患者可考虑戒烟干预以潜在改善CR率,但需外部验证。
局限性
- 回顾性多中心设计可能存在选择偏倚与未测量混杂。
- 吸烟戒烟获益需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Complete response (CR) after total neoadjuvant therapy (TNT) in rectal cancer is linked to favorable local control and enables non-operative management (NOM). Achieving high CR rates is crucial. As no standard TNT protocol exists, we aimed to assess the impact of clinical factors and different protocols on CR rates. METHODS: Rectal cancer patients undergoing TNT with curative intent between 2015 and 2024 were included in this retrospective multicenter analysis (DRKS00033000). The primary endpoint was CR. Predefined clinical and therapeutic variables were treated as covariates and evaluated as potential predictors of CR in a multivariable logistic regression model. RESULTS: Among 245 included patients (181 men) with a median age of 62 (Q1-Q3: 54-67) years, 113 (46.1%) reached a CR. Of those, 69 (28.2%) were active smokers. Short-course radiotherapy (SCRT) was applied in 107 (43.7%) patients. Chemoradiotherapy with pyrimidine-based monotherapy or concomitant oxaliplatin was used in 65 (26.5%) and 73 (29.8%) of patients, respectively. A median of 8 (Q1-Q3: 6-9) cycles of consolidation chemotherapy was administered. The CR likelihood increased with each additional chemotherapy cycle (OR 1.19, 95%-CI: 1.04-1.38). SCRT was associated with lower CR rates (OR 0.34, 95%-CI: 0.16-0.74) compared with concomitant pyrimidine-based chemoradiotherapy. Adding concomitant oxaliplatin to 5-FU did not further increase CR rates (OR 1.06, 95%-CI: 0.50-2.27). CR was more likely in non-smokers (OR 1.92, 95%-CI: 1.03-3.57). ESMO tumor classification and treatment duration were not associated with CR. CONCLUSION: More intensive TNT protocols were associated with higher CR rates. Smoking cessation may be beneficial but requires external validation.
引用
- Wurschi GW, Schneider M, Becker JN, et al. Clinical and treatment-related predictors of complete response after total neoadjuvant therapy for rectal cancer in a large multicenter analysis. Clin Transl Radiat Oncol. 2026. PMID: 41704720. doi:10.1016/j.ctro.2026.101120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。